Filtered By:
Infectious Disease: Epidemics
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 811 results found since Jan 2013.
Methyl(chloro)isothiazolinone contact allergy: a monocentric experience from Turkey
CONCLUSION: Although legal regulations related to MI and MCI/MI cause a decrease in the frequency of their sensitivities were still common causes of allergic contact dermatitis.PMID:37235630 | DOI:10.1080/15569527.2023.2217244
Source: Cutaneous and Ocular Toxicology - May 26, 2023 Category: Toxicology Authors: Didem Kazan Evren Odyakmaz-Demirsoy Rebiay Kiran Aysun Şikar-Aktürk Nilg ün Sayman Dilek Bayramg ürler Source Type: research
Contact Dermatitis to Isothiazolinone Preservatives
AbstractPurpose of ReviewAllergic contact dermatitis due to isothiazolinone derivatives is frequently observed both in consumers and in occupational exposures. In this article, we will review contact dermatitis to the most commonly used isothiazolinones, including trends in rates of allergy globally based on legislative changes, as well as looking at clinical presentation, diagnostic, and future considerations.Recent FindingsIsothiazolinone derivatives are ubiquitous in cosmetic, cleaning, and industrial products and are a significant cause of allergic contact dermatitis as highlighted by the epidemic of allergy seen with ...
Source: Current Dermatology Reports - May 3, 2023 Category: Dermatology Source Type: research
North American Contact Dermatitis Group Patch Test Results: 2019-2020
Conclusions: The epidemic of MI contact allergy in North America may have reached a plateau. Patch testing using a robust screening series, and supplemental allergens as indicated, is necessary for comprehensive evaluation of ACD.PMID:36917520 | DOI:10.1089/derm.2022.29017.jdk
Source: Dermatitis - March 14, 2023 Category: Dermatology Authors: Joel G DeKoven Erin M Warshaw Margo J Reeder Amber R Atwater Jonathan I Silverberg Donald V Belsito Denis Sasseville Kathryn A Zug James S Taylor Melanie D Pratt Howard I Maibach Joseph F Fowler Brandon L Adler Marie-Claude Houle Christen M Mowad Nina Bot Source Type: research
LEAPing into the void
The prevalence of immunoglobulin E –mediated food allergy has reached epidemic levels in much of the world, placing a substantial burden on affected patients, their families, and health systems.1 As of November 2022, there remains only 1 therapeutic option approved by the Food and Drug Administration for the treatment of food aller gy in the United States and it is only indicated for the treatment of pediatric peanut allergy. Meanwhile, no food allergy treatments are currently approved by the Therapeutic Goods Association, the governing body in Australia, where the study by Vale et al,2 to which this editorial refers, was carr ied out.
Source: Annals of Allergy, Asthma and Immunology - March 1, 2023 Category: Allergy & Immunology Authors: Christopher Warren, Sai R. Nimmagadda Tags: Editorial Source Type: research
Case studies expose deadly risk of mpox to people with untreated HIV
In June 2022, a young man in his 30s severely sick with mpox, the viral disease formerly known as monkeypox, was admitted to the Salvador Zubirán National Institute of Health Sciences and Nutrition hospital in Mexico City. Tests showed the patient was also HIV-positive, which he had not known, and that his blood had few CD4 cells, critical immune cells that HIV attacks. The man’s immune system was so weak it could not keep mpox in check and painful lesions kept spreading across his body, eating away at, or necrotizing, the flesh, according to HIV researcher Brenda Crabtree Ramirez, who was on his care team. Then the vir...
Source: Science of Aging Knowledge Environment - February 21, 2023 Category: Geriatrics Source Type: research
Case studies expose deadly risk of mpox in people with untreated HIV
In June 2022, a young man in his 30s severely sick with mpox, the viral disease formerly known as monkeypox, was admitted to the Salvador Zubirán National Institute of Health Sciences and Nutrition hospital in Mexico City. Tests showed the patient was also HIV-positive, which he had not known, and that his blood had few CD4 cells, critical immune cells that HIV attacks. The man’s immune system was so weak it could not keep mpox in check and painful lesions kept spreading across his body, eating away at, or necrotizing, the flesh, according to HIV researcher Brenda Crabtree Ramirez, who was on his care team. Then the vir...
Source: ScienceNOW - February 21, 2023 Category: Science Source Type: news
Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial
LEIDEN, THE NETHERLANDS, (January 18, 2023) – The Janssen Pharmaceutical Companies of Johnson & Johnson, together with a consortium of global partners, today announced the results of an independent, scheduled data review of the Phase 3 Mosaico study (also known as HPX3002/HVTN706) of Janssen’s investigational HIV vaccine regimen. The study’s independent Data and Safety Monitoring Board (DSMB) determined that the regimen was not effective in preventing HIV infection compared to placebo among study participants. No safety issues with the vaccine regimen were identified.In light of the DSMB’s determination, the Mo...
Source: Johnson and Johnson - January 18, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study
Lancet HIV. 2023 Jan 12:S2352-3018(22)00365-4. doi: 10.1016/S2352-3018(22)00365-4. Online ahead of print.ABSTRACTBACKGROUND: Long-acting injectable cabotegravir pre-exposure prophylaxis (PrEP) is recommended by WHO as an additional option for HIV prevention in sub-Saharan Africa, but there is concern that its introduction could lead to an increase in integrase-inhibitor resistance undermining treatment programmes that rely on dolutegravir. We aimed to project the health benefits and risks of cabotegravir-PrEP introduction in settings in sub-Saharan Africa.METHODS: With HIV Synthesis, an individual-based HIV model, we simul...
Source: Cancer Control - January 15, 2023 Category: Cancer & Oncology Authors: Jennifer Smith Loveleen Bansi-Matharu Valentina Cambiano Dobromir Dimitrov Anna Bershteyn David van de Vijver Katharine Kripke Paul Revill Marie-Claude Boily Gesine Meyer-Rath Isaac Taramusi Jens D Lundgren Joep J van Oosterhout Daniel Kuritzkes Robin Sch Source Type: research
